Artiva Biotherapeutics (ARTV) Enterprise Value (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Enterprise Value data on file, last reported at -$152.6 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 8.04% year-over-year to -$152.6 million in Q1 2026; TTM through Mar 2026 was -$152.6 million, a 8.04% increase from a year earlier, with the FY2025 full-year figure at -$108.0 million, up 41.75% from the prior year.
• Enterprise Value for Q1 2026 stood at -$152.6 million, down from -$108.0 million in the prior quarter.
• Over the last five years, Enterprise Value for ARTV reached as high as $73.1 million in Q2 2024 and fell as low as -$220.5 million in Q3 2025.
• Historically, Enterprise Value has averaged -$99.7 million across 4 years, with a median of -$125.2 million in 2025.
• On a YoY basis, Enterprise Value climbed as much as 236.14% in 2024 and fell as far as 1036.69% in 2024.
• Year by year, Enterprise Value stood at $19.8 million in 2023, then slumped by 1036.69% to -$185.4 million in 2024, then soared by 41.75% to -$108.0 million in 2025, then plunged by 41.31% to -$152.6 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$152.6 million in Q1 2026, -$108.0 million in Q4 2025, and -$220.5 million in Q3 2025.